Anzeige
Mehr »
Donnerstag, 17.09.2026 - Börsentäglich über 12.000 News
Heimlicher Börsenstar 2026?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
481 Leser
Artikel bewerten:
(2)

CBD Life Sciences Inc. (CBDL) enters the Kosher Market

SCOTTSDALE, AZ / ACCESSWIRE / March 4, 2021 / Today CBD Life Sciences (OTC PINK:CBDL), through its wholly-owned subsidiary, LBC Bioscience Inc. President & CEO, Lisa Nelson, announces that the company is entering the Kosher Market.

CBD Life Sciences Inc. is proud to announce that it is entering the Kosher Market. The products they are going to start working with are CBD Gummies, CBD Mints, Chamomile & CBD Enriched Tea, and CBD Horse Chews! President & CEO Lisa Nelson states, "We have a ton of customers demanding kosher products, and by doing this, it fulfills the current customer's needs on top of giving us access to an avenue of all new customers all around the world"! "This will also bring in a significant amount of revenue along with overall more sales globally as well."

Kosher certification is a standalone international quality standard that is increasingly prevalent in the food ingredients and retail sector. Walk into any supermarket in North America or Europe, and you will see that a significant portion of the food and drink is certified kosher, from the coveted Mars Bar, Marmite, to McCain's oven chips. In recent years demand for kosher certified products has increased dramatically. A quartz article, 2015, identified that less than 2% of the USA's population is Jewish, yet 41% of the country's packaged food is kosher. In 2009, the kosher industry was estimated to be worth around $17 billion, with an annual growth rate of around 15%, and in 2010 the New York Times claimed it was one of the hottest food trends.

Video Link of Greenhouse Facility: https://streamable.com/znupwq

CBD Life Sciences Inc. has already identified several potential cultivation sites and is aggressively pursuing amazing new opportunities in Arizona's new recreational cannabis market. This new law gives CBD Life Sciences Inc. the capability of offering licensed retailers CBD Life Sciences Inc. premium cannabis products which are then made available for sale to 1000's of future recreational cannabis customers in addition to current cannabis sales to existing medical-use dispensaries in Arizona.

The number of benefits CBD has is tremendous! These benefits include help with behavioral/neurological complications such as ADD/ADHD, anxiety, bipolar, OCD, PTSD, epilepsy, Parkinson's, osteoporosis, and ALS. CBD can also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn's, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension even our bodies way and ability to maintain homeostasis have all been said to benefit from CBD.

LBC Bioscience Inc. is well-stocked already as it is with some very high-quality CBD offerings - all at very reasonable prices. Check out LBC Bioscience Inc's newest product offerings, including its: 100mg CBD Bath Bombs, CBD Flower, CBD Hemp Smokes, 1500 MG Premium Berry Drops, 100MG CBD Tablets, and our tasty CBD Gumballs. Or shop our top selling products (based on order frequency), which include our CBD Pain Cream, CBD Oils, and CBD Pet Treats.

Why Shop LBC Bioscience?

  • Large Selection of Products (over 50 items and growing)
  • 100% USA Made Products "organic & kosher."
  • 30% off on all products using code "LBC30"

LBC Bioscience Inc. accepts Visa, MasterCard, American Express, Discover, etc.

Shareholders and interest holders may also stay current with LBC Bioscience Inc Updates:

LBC Bioscience Inc's Main Website at www.lbcbioscienceinc.com
Twitter: https://www.twitter.com/lbcbioscience
Facebook: https://www.facebook.com/lbcbioscience
Instagram: https://www.instagram.com/lbcbioscience

About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly-owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products, including CBD Drops, Gumballs, Honey Sticks, Pain Relief Creams, Anxiety & Sleep Supplements, Edibles, Coffee, Skincare Line, Pet Line, Tablets and more. LBC's products can be viewed and purchased on the Company's website at www.lbcbioscienceinc.com.

Ten Associates LLC
Contact: Thomas E. Nelson
Telephone: (480) 326-8577
Email: tenassociates33@gmail.com
Website: www.tenassociatesllc.com

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking.

SOURCE: CBD Life Sciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/633363/CBD-Life-Sciences-Inc-CBDL-enters-the-Kosher-Market

© 2021 ACCESS Newswire
KI braucht Strom
Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke.

Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation.

Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen.

Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.